Polymorphisms in the CASPASE genes and survival in patients with early-stage non-small-cell lung cancer

Seung Soo Yoo, Jin Eun Choi, Won Kee Lee, Yi Young Choi, Sin Kam, Min Jung Kim, Hyo Sung Jeon, Eung Bae Lee, Dong Sun Kim, Myung Hoon Lee, In-San Kim, Sanghoon Jheon, Jae Yong Park

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Purpose: This study was conducted to determine the impact of potentially functional polymorphisms in the CASPASE (CASP) genes on the survival of early-stage non-small-cell lung cancer (NSCLC) patients. Patients and Methods: Four hundred eleven consecutive patients with surgically resected NSCLC were enrolled. Nine potentially functional polymorphisms in the CASP3, CASP7, CASP8, CASP9, and CASP10 genes were investigated. The genotype and haplotype associations with overall survival (OS) and disease-free survival (DFS) were analyzed. Results: Patients with the rs2227310 GG genotype had a significantly decreased OS and DFS compared with patients with the CC + CG genotype (adjusted hazard ratio [aHR] for OS, 1.67; 95% CI, 1.19 to 2.35; P = .003; aHR for DFS, 1.62; 95% CI, 1.19 to 2.22; P = .002). The rs4645981C>T genotype also had a significant effect on OS and DFS (under a recessive model; aHR for OS, 2.00; 95% CI, 1.04 to 3.85; P = .04; aHR for DFS, 2.76; 95% CI, 1.58 to 4.80; P = .0003). When the rs2227310 and rs4645981 genotypes were combined, patients with one or two bad genotypes had worse OS and DFS compared with those who had zero bad genotypes (aHR for OS, 1.75; 95% CI, 1.25 to 2.45; P = .001; aHR for DFS, 1.66; 95% CI, 1.23 to 2.26; P = .001). Conclusion: The CASP7 rs2227310 and CASP9 rs4645981 polymorphisms may affect survival in early-stage NSCLC. The analysis of these polymorphisms can help identify patients at high risk for a poor disease outcome.

Original languageEnglish
Pages (from-to)5823-5829
Number of pages7
JournalJournal of Clinical Oncology
Volume27
Issue number34
DOIs
Publication statusPublished - 2009 Dec 1
Externally publishedYes

Fingerprint

Non-Small Cell Lung Carcinoma
Disease-Free Survival
Survival
Genotype
Genes
Caspase 3
Haplotypes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Yoo, S. S., Choi, J. E., Lee, W. K., Choi, Y. Y., Kam, S., Kim, M. J., ... Park, J. Y. (2009). Polymorphisms in the CASPASE genes and survival in patients with early-stage non-small-cell lung cancer. Journal of Clinical Oncology, 27(34), 5823-5829. https://doi.org/10.1200/JCO.2009.23.1738

Polymorphisms in the CASPASE genes and survival in patients with early-stage non-small-cell lung cancer. / Yoo, Seung Soo; Choi, Jin Eun; Lee, Won Kee; Choi, Yi Young; Kam, Sin; Kim, Min Jung; Jeon, Hyo Sung; Lee, Eung Bae; Kim, Dong Sun; Lee, Myung Hoon; Kim, In-San; Jheon, Sanghoon; Park, Jae Yong.

In: Journal of Clinical Oncology, Vol. 27, No. 34, 01.12.2009, p. 5823-5829.

Research output: Contribution to journalArticle

Yoo, SS, Choi, JE, Lee, WK, Choi, YY, Kam, S, Kim, MJ, Jeon, HS, Lee, EB, Kim, DS, Lee, MH, Kim, I-S, Jheon, S & Park, JY 2009, 'Polymorphisms in the CASPASE genes and survival in patients with early-stage non-small-cell lung cancer', Journal of Clinical Oncology, vol. 27, no. 34, pp. 5823-5829. https://doi.org/10.1200/JCO.2009.23.1738
Yoo, Seung Soo ; Choi, Jin Eun ; Lee, Won Kee ; Choi, Yi Young ; Kam, Sin ; Kim, Min Jung ; Jeon, Hyo Sung ; Lee, Eung Bae ; Kim, Dong Sun ; Lee, Myung Hoon ; Kim, In-San ; Jheon, Sanghoon ; Park, Jae Yong. / Polymorphisms in the CASPASE genes and survival in patients with early-stage non-small-cell lung cancer. In: Journal of Clinical Oncology. 2009 ; Vol. 27, No. 34. pp. 5823-5829.
@article{e03d9c9d19cf413ea7413683fddea594,
title = "Polymorphisms in the CASPASE genes and survival in patients with early-stage non-small-cell lung cancer",
abstract = "Purpose: This study was conducted to determine the impact of potentially functional polymorphisms in the CASPASE (CASP) genes on the survival of early-stage non-small-cell lung cancer (NSCLC) patients. Patients and Methods: Four hundred eleven consecutive patients with surgically resected NSCLC were enrolled. Nine potentially functional polymorphisms in the CASP3, CASP7, CASP8, CASP9, and CASP10 genes were investigated. The genotype and haplotype associations with overall survival (OS) and disease-free survival (DFS) were analyzed. Results: Patients with the rs2227310 GG genotype had a significantly decreased OS and DFS compared with patients with the CC + CG genotype (adjusted hazard ratio [aHR] for OS, 1.67; 95{\%} CI, 1.19 to 2.35; P = .003; aHR for DFS, 1.62; 95{\%} CI, 1.19 to 2.22; P = .002). The rs4645981C>T genotype also had a significant effect on OS and DFS (under a recessive model; aHR for OS, 2.00; 95{\%} CI, 1.04 to 3.85; P = .04; aHR for DFS, 2.76; 95{\%} CI, 1.58 to 4.80; P = .0003). When the rs2227310 and rs4645981 genotypes were combined, patients with one or two bad genotypes had worse OS and DFS compared with those who had zero bad genotypes (aHR for OS, 1.75; 95{\%} CI, 1.25 to 2.45; P = .001; aHR for DFS, 1.66; 95{\%} CI, 1.23 to 2.26; P = .001). Conclusion: The CASP7 rs2227310 and CASP9 rs4645981 polymorphisms may affect survival in early-stage NSCLC. The analysis of these polymorphisms can help identify patients at high risk for a poor disease outcome.",
author = "Yoo, {Seung Soo} and Choi, {Jin Eun} and Lee, {Won Kee} and Choi, {Yi Young} and Sin Kam and Kim, {Min Jung} and Jeon, {Hyo Sung} and Lee, {Eung Bae} and Kim, {Dong Sun} and Lee, {Myung Hoon} and In-San Kim and Sanghoon Jheon and Park, {Jae Yong}",
year = "2009",
month = "12",
day = "1",
doi = "10.1200/JCO.2009.23.1738",
language = "English",
volume = "27",
pages = "5823--5829",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "34",

}

TY - JOUR

T1 - Polymorphisms in the CASPASE genes and survival in patients with early-stage non-small-cell lung cancer

AU - Yoo, Seung Soo

AU - Choi, Jin Eun

AU - Lee, Won Kee

AU - Choi, Yi Young

AU - Kam, Sin

AU - Kim, Min Jung

AU - Jeon, Hyo Sung

AU - Lee, Eung Bae

AU - Kim, Dong Sun

AU - Lee, Myung Hoon

AU - Kim, In-San

AU - Jheon, Sanghoon

AU - Park, Jae Yong

PY - 2009/12/1

Y1 - 2009/12/1

N2 - Purpose: This study was conducted to determine the impact of potentially functional polymorphisms in the CASPASE (CASP) genes on the survival of early-stage non-small-cell lung cancer (NSCLC) patients. Patients and Methods: Four hundred eleven consecutive patients with surgically resected NSCLC were enrolled. Nine potentially functional polymorphisms in the CASP3, CASP7, CASP8, CASP9, and CASP10 genes were investigated. The genotype and haplotype associations with overall survival (OS) and disease-free survival (DFS) were analyzed. Results: Patients with the rs2227310 GG genotype had a significantly decreased OS and DFS compared with patients with the CC + CG genotype (adjusted hazard ratio [aHR] for OS, 1.67; 95% CI, 1.19 to 2.35; P = .003; aHR for DFS, 1.62; 95% CI, 1.19 to 2.22; P = .002). The rs4645981C>T genotype also had a significant effect on OS and DFS (under a recessive model; aHR for OS, 2.00; 95% CI, 1.04 to 3.85; P = .04; aHR for DFS, 2.76; 95% CI, 1.58 to 4.80; P = .0003). When the rs2227310 and rs4645981 genotypes were combined, patients with one or two bad genotypes had worse OS and DFS compared with those who had zero bad genotypes (aHR for OS, 1.75; 95% CI, 1.25 to 2.45; P = .001; aHR for DFS, 1.66; 95% CI, 1.23 to 2.26; P = .001). Conclusion: The CASP7 rs2227310 and CASP9 rs4645981 polymorphisms may affect survival in early-stage NSCLC. The analysis of these polymorphisms can help identify patients at high risk for a poor disease outcome.

AB - Purpose: This study was conducted to determine the impact of potentially functional polymorphisms in the CASPASE (CASP) genes on the survival of early-stage non-small-cell lung cancer (NSCLC) patients. Patients and Methods: Four hundred eleven consecutive patients with surgically resected NSCLC were enrolled. Nine potentially functional polymorphisms in the CASP3, CASP7, CASP8, CASP9, and CASP10 genes were investigated. The genotype and haplotype associations with overall survival (OS) and disease-free survival (DFS) were analyzed. Results: Patients with the rs2227310 GG genotype had a significantly decreased OS and DFS compared with patients with the CC + CG genotype (adjusted hazard ratio [aHR] for OS, 1.67; 95% CI, 1.19 to 2.35; P = .003; aHR for DFS, 1.62; 95% CI, 1.19 to 2.22; P = .002). The rs4645981C>T genotype also had a significant effect on OS and DFS (under a recessive model; aHR for OS, 2.00; 95% CI, 1.04 to 3.85; P = .04; aHR for DFS, 2.76; 95% CI, 1.58 to 4.80; P = .0003). When the rs2227310 and rs4645981 genotypes were combined, patients with one or two bad genotypes had worse OS and DFS compared with those who had zero bad genotypes (aHR for OS, 1.75; 95% CI, 1.25 to 2.45; P = .001; aHR for DFS, 1.66; 95% CI, 1.23 to 2.26; P = .001). Conclusion: The CASP7 rs2227310 and CASP9 rs4645981 polymorphisms may affect survival in early-stage NSCLC. The analysis of these polymorphisms can help identify patients at high risk for a poor disease outcome.

UR - http://www.scopus.com/inward/record.url?scp=73349124805&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=73349124805&partnerID=8YFLogxK

U2 - 10.1200/JCO.2009.23.1738

DO - 10.1200/JCO.2009.23.1738

M3 - Article

VL - 27

SP - 5823

EP - 5829

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 34

ER -